Transgenic GroupTSE:2342 +1.44%60 Interest Coverage is 3.45 as of Mar. 2026, which is 87% below its 10-year median of 25.68. GuruFocus rates TSE:2342 with a GF Score™ of 60/100 and a GF Value™ of 円257.43 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 377 Biotechnology companies, Transgenic Group ranks worse than 89.12% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Transgenic Group's
Operating Income
for the
six
months ended in Mar. 2026 was 円67 Mil. Transgenic Group's Interest Expense for the
six
months ended in Mar. 2026 was 円-19 Mil.
Transgenic Group's interest coverage for the quarter that ended in Mar. 2026 was 3.45.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Transgenic Group's Interest Coverage or its related term are showing as below:
TSE:2342'
s Interest Coverage Range Over the Past 10 Years
Min: 1.88 Med: 25.68 Max: 154.26
Current: 3.01
TSE:2342's Interest Coverage is ranked worse than 89.12% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs TSE:2342: 3.01
Transgenic Group (TSE:2342) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Transgenic Group Interest Coverage Related Terms
Transgenic Group Interest Coverage Historical Data
* Premium members only.
The historical data trend for Transgenic Group's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
TSE:2342 vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Transgenic Group's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Transgenic Group Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Transgenic Group's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Transgenic Group's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Transgenic Group (TSE:2342) has a Interest Coverage of 3.45 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Transgenic Group and its competitors. This is 87% below median its historical median of 25.68. Over the past decade, Transgenic Group's Interest Coverage has ranged from 1.88 to 154.26. According to the industry distribution chart, Transgenic Group ranks #336 out of 377 companies in the Biotechnology industry, placing it in the top 89.1%.
Is Transgenic Group's Interest Coverage too high?
Transgenic Group's current Interest Coverage of 3.45 is 87% below median its 10-year median of 25.68. Over the past 10 years, this metric has ranged from a low of 1.88 to a high of 154.26. The Biotechnology industry median Interest Coverage is 106.07. Transgenic Group's value of 3.45 is 96.7% below this industry median. Based on the distribution chart, Transgenic Group ranks #336 out of 377 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Transgenic Group has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Transgenic Group's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Transgenic Group ranks #336 out of 377 companies for Interest Coverage. This places Transgenic Group in the lower half of its industry. The industry median Interest Coverage is 106.07. Transgenic Group's value of 3.45 is 96.7% below this benchmark. Historically, Transgenic Group's own Interest Coverage has ranged from 1.88 to 154.26 over the past decade. While the company's 10-year median is 25.68 vs. the industry median of 106.07, Transgenic Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Transgenic Group's current Interest Coverage of 3.45 is 96.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Transgenic Group and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Transgenic Group's current Interest Coverage is 3.45, which is 87% below median its own 10-year median of 25.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgenic Group stock overvalued right now?
Based on GuruFocus' analysis, Transgenic Group (TSE:2342) is currently considered Modestly Undervalued. The stock's GF Value™ is 円257.43, compared to a current price of 円212.00 — trading 17.6% below its estimated fair value. The current Interest Coverage is 3.45, which is 87% below median its 10-year median of 25.68 and 96.7% below the Biotechnology industry median of 106.07. Transgenic Group's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Transgenic Group (TSE:2342), the current Interest Coverage is 3.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Transgenic Group (TSE:2342) Overvalued in 2026?
Based on GuruFocus' analysis, Transgenic Group stock appears to be undervalued.
The current stock price of 円212.00 is trading 17.6% below its estimated GF Value™ of 円257.43.
GuruFocus considers Transgenic Group to be Modestly Undervalued.
Key valuation signals for TSE:2342:
Interest Coverage: 3.45 (87% below median its 10-year median of 25.68)
GF Value™: 円257.43 vs. price of 円212.00 (17.6% below fair value)
Industry Position: 96.7% below the Biotechnology median (#336 of 377)
No single metric tells the full story. See the TSE:2342 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Transgenic Group Inc formerly Trans Genic Inc is engaged in offering assistance of non-clinical experiments using large animals and general rearing management work, and non-clinical trial service using large animals. The company has two segments: Drug discovery support business, and Investment and consulting business.
60GF Score
Get the complete analysis for TSE:2342
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2342 has been successfully added to your 
